ClinicalTrials.gg
RecruitingNCT05648591Updated Oct 1, 2026

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

A Phase 4 interventional study of Iloperidone in Schizophrenia and Bipolar I Disorder, sponsored by Vanda Pharmaceuticals. Recruiting at 11 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Vanda Pharmaceuticals · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.
Updated Oct 1, 2026Site recruiting status changedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing iloperidone in Schizophrenia — 2 open to participants now, 2 under way, 1 of them phase 3. iloperidone · Schizophrenia.

Planned enrollment
7th of 11
100 · median 260
Started
2023
the only one that year
Phase 4
3 of 11
1 open now
Registered
10th of 11
by date
Lead sponsor
7 of 11
Vanda Pharmaceuticals

Among the 11 studies testing iloperidone in Schizophrenia, this one is the 7th largest by planned enrollment, is the only one that started in 2023, is one of 3 in phase 4, and was the 10th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 11 studies testing iloperidone in Schizophrenia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About iloperidone

iloperidone: first FDA approval 2009 (FANAPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing iloperidone in Schizophrenia, or all of them as a file.
02

Study summary

To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.

03

Conditions studied

  • Schizophrenia
  • Bipolar I Disorder

Browse trials for

Keywords

  • fanapt
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is willing and able to provide assent and willing to complete all aspects of the study
  • Patient's parent or legal guardian willing and able to provide consent
  • Male or female patients 12 through 17 years of age (inclusive)
  • Clinical diagnosis of either schizophrenia or bipolar I disorder

Exclusion criteria

Exclusion Criteria:

  • Use of other drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
  • A positive test for drugs of abuse
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Iloperidone

    Open-label iloperidone

    Drug: Iloperidone

Interventions

  • oral tablet

    Also known as: VYV-683, FANAPT

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs) in the treatment period.

    Time frame: 1 year

07

Study locations

11 of 11 sites recruiting
  • Vanda Investigational Site
    Dothan, Alabama 36303, United States
    Recruiting
    • · Contact202-734-3400
  • Vanda Investigational Site
    Little Rock, Arkansas 72204, United States
    Recruiting
    • · Contact202-734-3400
  • Vanda Investigational Site
    Denver, Colorado 80202, United States
    Recruiting
    • · Contact202-734-3400
  • Vanda Investigational Site
    Atlanta, Georgia 30318, United States
    Recruiting
    • · Contact202-734-3400
  • Vanda Investigational Site
    Atlanta, Georgia 30331, United States
    Recruiting
    • · Contact202-734-3400
  • Vanda Investigational Site
    Decatur, Georgia 30030, United States
    Recruiting
    • · Contact202-734-3400
  • Vanda Investigational Site
    Kinston, North Carolina 28501, United States
    Recruiting
    • · Contact202-734-3400
  • Vanda Investigational Site
    Cincinnati, Ohio 45221, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Garfield Heights, Ohio 44125, United States
    Recruiting
    • · Contact202-734-3400
  • Vanda Investigational Site
    Westlake, Ohio 44145, United States
    Recruiting
    • · Contact202-734-3400
  • Vanda Investigational Site
    Everett, Washington 98201, United States
    Recruiting
    • · Contact202-734-3400
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Dec 2028, 67 months after the start.

Of 88 phase 4 interventional studies under Schizophrenia, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's planned 67 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Mar 2026 → Dec 2028 and completion Nov 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2022
First posted
Dec 13, 2022
StartActual
May 24, 2023
Primary completionEst.
Dec 31, 2028was Mar 2026
CompletionEst.
Dec 31, 2028was Nov 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added. Vanda Investigational Site is now Recruiting
Show 2 added (2 United States)
  • Vanda Investigational Site · Dothan, United States
  • Vanda Investigational Site · Kinston, United States
Oct 1, 2026
Primary completion
Mar 31, 2026→Dec 31, 2028
Oct 1, 2026
Study completion
Nov 30, 2026→Dec 31, 2028
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    2 sites added. Vanda Investigational Site is now Recruiting
    Show 2 added (2 United States)
    • Vanda Investigational Site · Dothan, United States
    • Vanda Investigational Site · Kinston, United States
    Primary completion Mar 31, 2026→Dec 31, 2028
    Study completion Nov 30, 2026→Dec 31, 2028
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05648591
Responsible party
Sponsor
First posted
Dec 13, 2022
Start date
May 24, 2023
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Vanda Pharmaceuticals Inc.
Contact
clinicaltrials@vandapharma.com
202-734-3400

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iloperidone

Start the discussion